Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Safety and efficacy of azacitidine in myelodysplastic syndromes Vigil CE; Martin-Santos T; Garcia-Manero GDrug Des Devel Ther 2010[Sep]; 4 (ä): 221-9PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. CONCLUSION: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.|Antimetabolites, Antineoplastic/administration & dosage/adverse effects/*therapeutic use[MESH]|Azacitidine/administration & dosage/adverse effects/*therapeutic use[MESH]|Disease Progression[MESH]|Drug Administration Schedule[MESH]|Humans[MESH]|Leukemia, Myeloid, Acute/prevention & control[MESH]|Myelodysplastic Syndromes/complications/*drug therapy[MESH]|Survival[MESH] |
